Performance of capecitabine in novel combination therapies in colorectal cancer
- 21 May 2021
- journal article
- other
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 33 (6) , 375-389
Abstract
Colorectal cancer is one of the most common cancers throughout the world, and no definitive cure has ever been found. Perhaps a new insight into the effectiveness of chemotherapy drugs could help better treat patients. Targeted therapies have significantly improved the median overall survival of colorectal cancer patients. One of the standard chemotherapy regimens used for colorectal cancer is capecitabine, which is important in monotherapy and combination therapies. Capecitabine, with other chemotherapeutic agents (irinotecan, oxaliplatin, perifosine, 17-allylamino-17-demethoxygeldanamycin, aspirin, celecoxib, statins, quinacrine, inositol hexaphosphate and inositol, cystine/theanine, curcumin, and isorhamnetin), and biological ones (antibodies) plays an important role in the inhibition of some signaling pathways, increasing survival, reducing tumor growth and side effects of capecitabine. However, some drugs, such as proton pump inhibitors, are negatively related to capecitabine; therefore, the purpose of this work is to review and discuss the performance of capecitabine combination therapies in colorectal cancer.Keywords
This publication has 123 references indexed in Scilit:
- Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trialsThe Lancet, 2011
- Dissecting DNA hypermethylation in cancerFEBS Letters, 2010
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studiesJournal of Cancer Research and Clinical Oncology, 2009
- Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studiesThe Lancet, 2007
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Regulation of the mevalonate pathwayNature, 1990